Department of Physics, University of Helsinki, Helsinki, Finland.
Neuroscience Center/HiLIFE, University of Helsinki, Helsinki, Finland.
Trends Biochem Sci. 2024 May;49(5):445-456. doi: 10.1016/j.tibs.2024.02.001. Epub 2024 Mar 2.
TrkB (neuronal receptor tyrosine kinase-2, NTRK2) is the receptor for brain-derived neurotrophic factor (BDNF) and is a critical regulator of activity-dependent neuronal plasticity. The past few years have witnessed an increasing understanding of the structure and function of TrkB, including its transmembrane domain (TMD). TrkB interacts with membrane cholesterol, which bidirectionally regulates TrkB signaling. Additionally, TrkB has recently been recognized as a binding target of antidepressant drugs. A variety of different antidepressants, including typical and rapid-acting antidepressants, as well as psychedelic compounds, act as allosteric potentiators of BDNF signaling through TrkB. This suggests that TrkB is the common target of different antidepressant compounds. Although more research is needed, current knowledge suggests that TrkB is a promising target for further drug development.
TrkB(神经元酪氨酸激酶受体-2,NTRK2)是脑源性神经营养因子(BDNF)的受体,是活性依赖性神经元可塑性的关键调节因子。在过去的几年中,人们对 TrkB 的结构和功能,包括其跨膜结构域(TMD)有了越来越多的了解。TrkB 与膜胆固醇相互作用,双向调节 TrkB 信号。此外,TrkB 最近被认为是抗抑郁药物的结合靶点。各种不同的抗抑郁药物,包括典型和快速作用的抗抑郁药物,以及迷幻化合物,作为 BDNF 信号的别构增强剂通过 TrkB 起作用。这表明 TrkB 是不同抗抑郁化合物的共同靶点。尽管还需要更多的研究,但目前的知识表明,TrkB 是进一步药物开发的有前途的靶点。